Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Gets Japanese Approval For Actemra For Rheumatoid Arthritis

This article was originally published in PharmAsia News

Executive Summary

Japan's Chugai Pharmaceutical has received approval to market its Actemra (tocilizumab) antibody drug for treating rheumatoid arthritis in addition to its original indication for Castleman's disease. The approval is expected to be made official in April and the company expects to begin marketing it to the more than 700,000 people in Japan with rheumatoid arthritis. Chugai expects the drug to be a blockbuster, generating $44.5 million in sales in 2008. The firm also is teaming with Roche Holding to market the drug in Europe and North America. (Click here for more - a subscription may be required

You may also be interested in...



U.S. FDA Advisory Committee Gives Thumbs Up To Chugai’s Actemra RA Treatment

TOKYO - The U.S. FDA's Arthritis Advisory Committee voted 10 to one for approving Actemra (tocilizumab) a rheumatoid arthritis treatment that Japan's Chugai Pharmaceutical already is marketing for Castleman's disease, Chugai and partner Roche announced July 30

Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec

SINGAPORE - Chugai attributes the success of its development program for the novel interleukin-6 receptor-inhibiting Actemra (tocilizumab) to its partnership with Roche, Chugai Business Development General Manager Kimio Nishimura told Biomedical Asia 2008 attendees in Singapore April 16

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel